Comparison of the risk of drop-out from opioid maintenance treatment in patients using naltrexone ımplants vs. oral buprenorphine-naloxone Opioid kullanım bozukluğu sürdürüm tedavisinde naltrekson implant ile oral buprenorfin-nalokson kullanan hastaların tedaviyi yarıda bırakma risklerinin karşılaştırılması


Creative Commons License

Kırlı U., Nart O.

Klinik Psikiyatri Dergisi, cilt.24, sa.3, ss.342-349, 2021 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5505/kpd.2021.37084
  • Dergi Adı: Klinik Psikiyatri Dergisi
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Psycinfo, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.342-349
  • Anahtar Kelimeler: Naltrexone, Buprenorphine-Naloxone Combination, Opioid Use Disorder, Maintenance Treatment, Polysubstance Use
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: Through increasing prevalence, opioid use disorder has been an important public health problem. The aim of this study is to compare the risk of drop-out from opioid use disorder maintenance treatment in patients using naltrexone implants vs. oral buprenorphine-naloxone, and to assess some sociodemographic and clinical correlates of drop-out. Method: The study has a retrospective-cohort design. All patients who completed the 21-days inpatient detoxification treatment between January 1st – November 1st, 2019 in a specialized alcohol and substance abuse treatment centre, and planned to be treated with either oral buprenorphine-naloxone or naltrexone implants were included in the study (n: 107). The associations between the drop-outs from the maintenance treatment and the treatment used (buprenorphine-naloxone or naltrexone implants), sociodemographic/clinical characteristics were assessed via multivariate cox regression. Results: No large or significant differences in sociodemographic and clinical characteristics were found between the two treatment groups. Both univariate and multivariate analysis showed no significant differences in the risk of drop-out from treatment between patients using oral buprenorphine-naloxone vs. naltrexone implants (Hazard Ratio: 1.39, %95CI: 0.82-2.35, p: 0.2). Multivariate analysis showed that presence of another substance use in addition to opioid use was significantly associated with the risk of drop-out (Hazard Ratio: 1,79, %95CI: 1,06-3,16, p: 0,04). Discussion: Results suggest no significant difference in the risk of drop-out from opioid maintenance treatment in patients using naltrexone implants vs. oral buprenorphine-naloxone. Additional substance use should be carefully considered while planning opioid use disorder maintenance treatment.